# Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

> **NCT07722507** · — · NOT_YET_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 40 (estimated)

## Conditions studied

- Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis
- Progressive Pulmonary Fibrosis

## Interventions

- **DRUG:** Antifibrotic therapy

## Key facts

- **NCT ID:** NCT07722507
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722507, "Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*